Wednesday, September 20, 2017| Johnson & Johnson Vision Care

EyewireTV - J&J Acquires Sightbox; Phase 3 GA Drug Candidate Fails

In this week’s EyewireTV, Johnson & Johnson Vision acquires Sightbox, an online membership-based subscription service for contact lens wearers; and Genentech’s lampalizumab, a drug candidate being evaluated for the treatment of geographic atrophy due to AMD, fails a phase 3 trial. Also, Carl Zeiss Meditec announces the US launch of its next-generation, ultra-widefield fundus imaging system, the CLARUS 500.

Watch Video

Wednesday, September 06, 2017| Acquisitions, Mergers, Alcon, Alcon, CyPass Micro-Stent, Johnson & Johnson Vision Care, Medicare, Novartis, TearScience

EyewireTV - J&J Completes TearScience acquisition; New Novartis CEO

In this week’s EyewireTV, Johnson & Johnson Vision completes its acquisition of privately held TearScience; and Novartis CEO Joseph Jimenez announces he is stepping down from his role in January and will be replaced by Vasant Narasimhan, the company's current global head of drug development and chief medical officer. Also, Alcon announces that the Unique Procedure Code for the CyPass Micro-Stent has become effective, paving the way for Medicare reimbursement.

Watch Video

Wednesday, August 30, 2017| AcuFocus, Clinical Trials, FDA Approval/Clearance, Intraocular lens, IOL, IOLs, prosthetic vision systems, Second Sight Medical Products, stem cell therapy

EyewireTV — Stem Cell Overhaul; New Visual Prothesis System

In this week’s EyewireTV, the FDA announces plans to crack down on stem cell clinics marketing and selling unapproved and potentially harmful therapies; and Second Sight Medical Products receives conditional approval from the FDA to begin the first human clinical trial of the Orion Cortical Visual Prosthesis System. Also, AcuFocus announces the publication of a European post-market study of the IC-8 small-aperture IOL.

Watch Video

Wednesday, August 23, 2017| Acquisitions, Mergers, Carl Zeiss Meditec, Nidek, Product Releases

EyewireTV — Retinal Imaging for Alzheimer’s; Zeiss Acquisition

In this week’s EyewireTV, a new study shows that noninvasive retinal imaging may detect the pathological hallmarks of Alzheimer’s disease; and Carl Zeiss Meditec acquires Veracity Innovations, maker of a cloud-based platform that provides eye doctors access to clinical data at each step in the treatment regimen. Also, Nidek announces the launch of the the TS-310, a tabletop subjective refraction system that combines refractor and chart capabilities in a compact footprint.

Watch Video

Wednesday, August 16, 2017

EyewireTV — Solar Eclipse Safety; Eyetube3D Launches

As Americans prepare for the first total solar eclipse in the United States in 37 years, EyewireTV provides tips on how to safely view the rare event and advice to physicians who may see patients with solar retinopathy; and a year after launching in the United States, Shire applies for European approval for its blockbuster dry eye drug lifitegrast. Also, Eyetube announces the launch of Eyetube3D, a new channel that allows physicians with a virtual reality headset to view 3-dimensional surgical cases online.

Watch Video

Wednesday, August 09, 2017| Cornea, FDA Approval/Clearance, Intraocular Pressure, IOP, Johnson & Johnson Vision Care, Meibomian Gland Dysfunction, MGD, Optovue, TearScience, Valeant

EyewireTV — J&J Agrees To Buy TearScience; FDA Clears Epi-Mapping Software

In this week’s EyewireTV, Johnson & Johnson Vision continues to boost its eye care portfolio as it announces a definitive agreement to acquire TearScience, a provider of devices that detect and treat meibomian gland dysfunction; and the FDA rejects Valeant's new drug application for IOP-lowering eye drop latanoprostene bunod, citing manufacturing issues. Also, the FDA clears Optovue's epithelial thickness mapping software (epi-mapping) for quantitative measurements of the epithelial and stromal layers of the cornea.

Watch Video
Load More